Background

The COVID-19 pandemic highlighted the urgent need for novel diagnostic and therapeutic tools. Current tests and treatments face limitations in sensitivity, specificity, and adaptability to viral mutations.

Single-chain variable fragment antibodies (scFvs) offer advantages due to their stability, modularity, and ability to target specific viral epitopes. By immobilizing scFvs in diagnostic devices and embedding them in polymeric scaffolds, it becomes possible to combine precise detection with therapeutic inhibition. Cryo-EM and surface plasmon resonance studies further strengthen the ability to select optimal antibody variants.

The project

COVITRAP pursues the following objectives:

• Develop a diagnostic tool with scFvs immobilized on glass-based microdevices, integrated with DLS and spectrophotometry detection systems.
• Optimize scFv portfolios through epitope screening and structural analysis, ensuring coverage of diverse viral binding sites.
• Design scFv-polymer therapeutics using site-specific functionalization for multivalent virus binding and inhibition.
• Validate antibodies and scaffolds in BSL-3 laboratories with clinical SARS-CoV-2 isolates.
• Establish a translational pipeline from scFv discovery to diagnostic prototypes and therapeutic candidates.

The science

The consortium integrates expertise in microengineering, polymer chemistry, and infection biology:

• Ghent University (Belgium): Development of diagnostic microsystems with optical detection.
• Fraunhofer IAP (Germany): Protein–polymer conjugation, scFv immobilization, and therapeutic scaffold design.
• Universitas Padjadjaran (Indonesia): BSL-3 laboratory validation of scFv antibodies and therapeutic candidates against SARS-CoV-2 isolates.

The team

The COVITRAP partners are:

• Prof. Dr. Jeroen Missinne (Coordinator), Ghent University (UGent), Belgium
• Dr. Ulrich Glebe, Fraunhofer Institute for Applied Polymer Research (IAP), Germany
• Dr. Atik Nur, Universitas Padjadjaran (UNPAD), Indonesia

Contact:

Prof. Dr. Jeroen Missinne                        Email: jeroen.missinne@ugent.be 

Background

Emerging and re-emerging viral infections such as Dengue and COVID-19 highlight the urgent need for new antiviral agents. Current antiviral options are limited, and broad-spectrum antivirals are rare.

Fungi represent a largely untapped source of bioactive secondary metabolites with antimicrobial potential. Previous collaborations among the partners have yielded novel antibiotics from endophytic and invertebrate-associated fungi. This project expands these efforts to antiviral discovery, leveraging established compound libraries and access to new fungal biodiversity.

The project

Antiviralfun pursues the following objectives:

• Screen fungal metabolites from existing and newly collected species for antiviral activity.
• Develop and optimize antiviral bioassays against Dengue virus and SARS-CoV-2, adaptable to future emerging viruses.
• Characterize biological activities of promising compounds, including cytotoxicity, antifungal, and antibacterial properties.
• Benchmark lead candidates against EU-OPENSCREEN’s pilot compound library.
• Characterize producing fungal strains to ensure reproducibility and optimal production.
• Deliver at least three comprehensively characterized lead compounds for further medicinal chemistry development.

The science

The project combines expertise in natural product discovery, infection biology, and biodiversity research:

• Helmholtz Centre for Infection Research (Germany): Antiviral screening platforms, BSL-3 laboratories, and compound profiling.
• National Center for Genetic Engineering and Biotechnology (Thailand): Biodiversity exploration and fungal metabolite discovery.
• Institute of Microbiology, Czech Academy of Sciences (Czech Republic): Fungal taxonomy, metabolite extraction, and profiling.
• EU-OPENSCREEN (Germany): High-throughput screening and compound library resources.

Expected outcomes include novel antiviral leads, validated assays for emerging viruses, and contributions to fungal biodiversity repositories.

The team

The Antiviralfun partners are:

• Prof. Ursula Bilitewski (Coordinator), Helmholtz Centre for Infection Research, Germany
• Dr. Jennifer Luangsa-ard, National Center for Genetic Engineering and Biotechnology, Thailand
• Dr. Miroslav Kolarik, Institute of Microbiology, Czech Academy of Sciences, Czech Republic
• Dr. Bahne Stechmann, EU-OPENSCREEN, Germany

Contact:

Prof. Ursula Bilitewski               Email: ursula.bilitewski@helmholtz-hzi.de 

Background

Neisseria gonorrhoeae causes gonorrhea, the second most common sexually transmitted infection worldwide, with approximately 87 million new cases annually. The pathogen is listed as a high-priority organism by the WHO due to rapidly rising antimicrobial resistance, including strains resistant to ceftriaxone and azithromycin.

The DXR enzyme, essential in the methylerythritol phosphate (MEP) pathway for isoprenoid biosynthesis, is absent in humans but critical for bacterial survival. This makes it an ideal drug target. Previous studies have shown DXR inhibitors are effective in E. coli, Y. pestis, M. tuberculosis, and apicomplexan parasites. NONEGON aims to apply this concept to N. gonorrhoeae.

The project

NONEGON pursues the following objectives:

• High-throughput screening of up to 100,000 synthetic compounds for DXR inhibition.
• Drug repurposing screen of 6,500 approved drugs to identify candidates with immediate translational potential.
• Natural product library screen including thousands of pure compounds and herbal extracts.
• Structure-based virtual screening of millions of commercially available compounds.
• Biological evaluation of promising hits for antibacterial activity, cytotoxicity, and ADME properties.
• Prioritization of repurposed drugs with DXR activity for accelerated clinical progression.

The science

The project integrates computational drug discovery, molecular biology, and antimicrobial testing:

• Fraunhofer IME (Germany): High-throughput screening and drug discovery expertise.
• Yildiz Technical University (Turkey): Structure-based drug design, molecular docking, protein purification, and enzyme kinetics.
• Mahidol University (Thailand): Infectious disease research, antibacterial testing, and translational studies.

This interdisciplinary approach maximizes the chances of identifying potent DXR inhibitors and provides a pipeline from virtual screening to in vitro validation and potential clinical candidates.

The team

The NONEGON partners are:

Dr. Björn Windshügel (Coordinator), Fraunhofer Institute for Molecular Biology and Applied Ecology (Fraunhofer IME), Germany

Prof. Dilek Balik, Yildiz Technical University (YTU), Turkey

Dr. Ratana Lawung, Mahidol University (MU), Thailand

Contact:

Dr. Björn Windshügel                Email: bjoern.windshuegel@ime.fraunhofer.de 

Background

The COVID-19 pandemic underscored the urgent need for advanced models of infectious respiratory diseases. Current cell culture systems fail to mimic the complexity of the human lung, while animal models lack essential properties of the human pulmonary blood-air barrier, often requiring costly humanized transgenic systems.

To advance understanding, there is a need for experimental platforms that reproduce the pulmonary microphysiology, particularly the alveolar epithelial cells targeted by SARS-CoV-2. Such models can reveal mechanisms of viral entry and progression, while supporting the evaluation of novel therapeutic interventions.

The project

MicroLung pursues the following objectives:

• Develop pulmonary blood-air barrier models using microfluidic and tissue-engineered systems.
• Design nanoparticles functionalized with ACE2-specific peptides to mimic viral binding and compete with SARS-CoV-2 for cell entry.
• Engineer nanoparticles carrying antiviral agents for drug transport studies across the lung barrier.
• Validate models with SARS-CoV-2 isolates in biosafety level 3 laboratories to compare nanoparticle results with actual viral behavior.
• Foster transnational collaboration between partners for nanoparticle design, microfluidic systems, and virus validation studies.

The science

The consortium integrates complementary expertise:

• Microfluidic and tissue engineering platforms to recreate the pulmonary barrier (ACU, Turkey).
• Nanoparticle-based therapeutic delivery systems and functional testing (Fraunhofer IKTS, Germany).
• In-vitro infection studies with SARS-CoV-2 isolates in biosafety level 3 facilities (UGM, Indonesia).

Outcomes include novel lung models for COVID-19 research, nanoparticle-based therapeutic concepts, and platforms applicable to other respiratory viruses beyond SARS-CoV-2.

The team

The MicroLung partners are:

Prof. Dr. Vasif Nejat Hasirci (Coordinator), Acibadem Mehmet Ali Aydinlar University (ACU), Turkey

Dr. Joerg Opitz, Fraunhofer Institute for Ceramic Technologies and Systems (IKTS), Germany

Assoc. Prof. Ika Dewi Ana, Universitas Gadjah Mada (UGM), Indonesia

Contact:

Prof. Dr. Vasif Nejat Hasirci           Email: vasif.hasirci@acibadem.edu.tr 

Background

The COVID-19 pandemic and earlier coronavirus outbreaks (SARS, MERS) demonstrate the ongoing threat of zoonotic spillovers. Vaccines inducing both antibody and T-cell responses against conserved viral regions are essential. However, T-cell epitopes vary across populations due to differences in HLA allele prevalence.

Most studies so far have focused on Caucasian populations, neglecting alleles like HLA-A*24:07, common in Southeast Asia. This project brings together partners from Indonesia, Thailand, and Germany to identify SARS-CoV-2-specific epitopes relevant to these populations, filling a major research gap.

The project

TimCovSEAEu pursues the following objectives:

• Identification of T-cell epitopes: Use immunoinformatics algorithms (SYFPEITHI, NetMHCpan) to predict SARS-CoV-2 CD4+ and CD8+ epitopes for the most frequent HLA class I (15 alleles) and HLA-DR (6 alleles) in Southeast Asia.
• Experimental validation: Conduct high-throughput ELISpot assays using PBMCs from COVID-19 convalescent donors to confirm T-cell responses.
• Immunological characterization: Compare T-cell responses in COVID-19 convalescents versus uninfected individuals to assess immunity and memory.
• Application for vaccines and immunotherapies: Provide candidate epitopes for multi-peptide vaccines and adoptive T-cell therapies.

The science

The consortium integrates computational prediction with experimental validation:

• Immunoinformatics analysis of the SARS-CoV-2 proteome.
• High-throughput epitope screening using ELISpot assays.
• Comparative immunology across Indonesian, Thai, and European cohorts.
• Clinical translation through collaboration with hospitals and immunotherapy centers.

Expected outcomes include novel epitope panels for monitoring T-cell memory, deeper insights into cross-population immunity, and candidate structures for next-generation vaccines and therapies.

The team

The TimCovSEAEu partners are:

Ph.D. Marsia Gustiananda (Coordinator), Indonesia International Institute for Life Sciences (i3L), Indonesia

PD Dr. med. Juliane Sarah Walz, Robert Bosch Center for Tumor Diseases, Robert Bosch Hospital Stuttgart (RBCT), Germany

Assist. Prof. Jaturong Sewatanon, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Contact:

Ph.D. Marsia Gustiananda               Email: marsia.gustiananda@i3l.ac.id 

Background

The current antibiotic crisis represents a global problem of fundamental importance, comparable with other global challenges as e.g. climate change or sustainable energetics, but far less discussed in the society. Without active approach right now the, the infectious diseases will soon become the most frequent cause of death worldwide.

The TIC-TAC project consists of two objectives aiming to avert the threat of an antibiotic crisis: 1) Knowledge-based hunt for novel bioactive metabolites derived from plants and microorganisms and 2) Development of promising compounds into drugs.

The project

Within the Objective 1 we will create a collection of 1000+ unique Actinobacteria strains, a corresponding number of culture broth crude extracts, and 100+ plant crude extracts. Metabolites in the crude extracts will be separated into 5000+ fractions and these will be tested for a broad spectrum of biological activities, particularly against clinically important pathogenic microorganisms (including MDR strains). These include Mycobacterium tuberculosis (causing tuberculosis), G- bacteria, Plasmodium falciparum (causing malaria), Zika virus, and others.

The Objective 2 aims to the development of previously patented hybrid lincosamide derivatives developed by the Czech team and further compounds suggested by SEA teams into drugs.

The science

Our strategy to combat the antibiotic (antibacterial and antiparasitic) crisis exploits natural products that proved to be a superior source of druggable compounds. We will use modern biology and chemistry methodology for this purpose – knowledge-based genome mining (oriented on the search for biosynthetic pathways utilizing alkyl-proline derivatives, which are far more efficient when compared to L-proline incorporating compounds), mass spectrometry-based metabolomics (GNPS molecular networking + other bioinformatics tools); and we will focus on testing multiple targets, i.e. multiple pathogens including those clinically most important and threatening. CZ team will provide a collection of the clinically most dangerous bacterial strains from the WHO list for antimicrobial activity testing; Thai team possess a collection of P. falciparum strains for antimalarial properties and resistant M. tuberculosis strains for antimicrobial properties testing. Unique sources of bioactive metabolites from yet underexplored Thai and Indonesian biotopes will be used to search for new compounds.

Project partners:

Institute of Microbiology, Czech Academy of Sciences, Czech Republic (PI and main coordinator - Jiri Janata)

School of Pharmacy, Walailak University, Thailand  (PI and coordinator for SEA - Amit Jaisi)

Faculty of Pharmacy, Andalas University, West Sumatra, Indonesia (Deri Dachriyanus)

Research Centre for Chemistry, Indonesian Institute of Science (LIPI), Indonesia (Abdi Wira Septama)

Contact:

Jiri Janata, Ph.D.                   

Background

Tuberculosis (TB) remains an urgent public health threat and a leading infectious cause of death worldwide. Despite long-term support such as directly observed treatment to help patients complete their treatment, non-adherence to TB treatment is known to be suboptimal which leads to treatment failures, poor quality of life, or development of multidrug-resistant tuberculosis. The reasons underlying non-adherence are not entirely independent and are heterogeneous. Digital interventions are gradually being integrated into practice because of affordable mobile electronic devices in many settings. However, the flaws of some of the existing digital technologies to improve medication adherence are that they are not tailored to patients’ individual problems. The existing apps are commonly delivered as a one-size-fit-all intervention, assuming that the reasons for non-adherence are the same for the patients. We propose a novel app that will not only screen patients who are being non-adherent, but will also guide healthcare providers to identify patients’ individual problem and to deliver the recommended personalized strategies

The Project

The aim of this project is to develop a smart-phone application for health care providers that can be used for personalized interventions to improve medication adherence of TB patients (SMART-TB) in Indonesia. The proposed apps can be applied in primary, secondary and tertiary health facilities in Indonesia and can be adapted to other high-TB prevalence countries.

The Science

The SMART-TB app will be developed in Bahasa with five main functions, called SIM-CAR functions, as follow: Screening (to identify medication adherence problems in TB patients), Intervening (to intervene in TB patients’ individual problems of medication adherence), Monitoring (to monitor TB patients in taking their medication), Communicating (to communicate about medication adherence among TB officers (pharmacist/ TB programmer), TB patients, and TB experts), and Administrating (to register patient information related to medication adherence until the TB treatment outcomes are measured). In the first year, we will develop a prototype of the SMART-TB. Its content development will be performed through a literature review and qualitative study. In the second year, pilot testing will be conducted to validate the content and implementation of the prototype in a small-scale population representing rural and urban area. In the third year, the content and system of the SMART-TB will be validated based on the results of the pilot testing.

The Team

The SMART-TB partners are:

• Coordinator: Rizky Abdulah, PhD, Universitas Padjadjaran, Indonesia
• Prof. Jutti Levita, Universitas Padjadjaran, Indonesia
• Ivan S. Pradipta, PhD, Universitas Padjadjaran, Indonesia
• Sofa D. Alfian, M.PH, PharmD, Universitas Padjadjaran, Indonesia
• Prof. dr. Eelko Hak, University of Groningen, Groningen, the Netherlands
• Prof. Katja Taxis, University of Groningen, Groningen, the Netherlands
• Prof. Jan-Willem Alffenaar, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
• Job F. M. van Boven, PhD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
• Prof. Esin Aki Yalcin, Ankara University, Ankara, Turkey
• Prof. Federico Gago, University of Alcala, Madrid, Spain

• Ly Le, PhD, Ho Chi Minh City International University, Vietnam

   

Contact: 

Rizky Abdulah, PhD; Email: r.abdulah@unpad.ac.id 

Background

Angiostrongylus cantonensis is a unique pathogen that is predominantly dependent on invasive rodent and mollusc hosts. Continuing spread of these organisms has led to wide distribution of AEM throughout the tropics. The majority of clinical cases are reported from SE Asia (the highest incidence in Thailand), however, the disease is broadly distributed in Pacific regions (French Polynesia, Hawaii, Australia) with recent invasions into continental USA. Recently, the pathogen was discovered in rats in the Canary Islands and two year ago, clinical human AEM cases were reported in France. Most recently, in 2019, the parasite was detected in Mallorca, Spain, demonstrating immediate risk of spread in southern parts of EU territories.

The Project

This project aims to develop a novel diagnostic tool for human eosinophilic meningitis caused by Angiostrongylus cantonensis, namely a LAMP assay for AC detection in clinical cases, in various organism that serve as infection sources and in environmental samples. Our project consortium combines teams with expertise in various fields of human and veterinary medicine, ecology and infection biology. Project benefits from experience of EU and Thailand teams with development of molecular-based diagnostic tools including the LAMP technology, equipment and experimental work with AC, combined with partnerships/collaboration with research teams from countries with high incidences of AEM clinical cases in SE Asia (Philippines, Thailand, Indonesia). With synergic involvement of adjunct research partners from Australia, Spain, Italy and UK, the project team aims at (i) technological progress in AEM clinical diagnostics, (ii) detection of AC in food chains and (iii) understanding of local as well as global epidemiology of this emerging disease.

The Science

As the epidemiology of AEM involves humans, various mammals and birds, invertebrates, as well as environmental components, the One Health approach represents an ultimate avenue in diagnostics and prevention of this emerging disease.  As a result, composition of the consortium, the project involves experimental activities associated with development, optimization and experimental testing of developed assays, alongside clinical evaluation in medical facilities in SEA and detection of AC in the food chain and environment. Proposed LAMP diagnostics offer a range of advantages over other diagnostic approaches as it is applicable in field and clinical conditions as does not require time consuming and technologically demanding steps. The results of this project can be immediately disseminated and translated into sensitization of local populations and public awareness, respecting given cultural context and stage of development of partnering ASEAN countries.  

The Team

• Prof. David Modry, Dr. Vojto Baláž and Barbora Fecková, DVM / Biology Center of Czech Academy of Sciences v.v.i., České Budějovice, Czech Republic

• Muhammad Hambal, DVM, Ph.D. / Syiah Kuala University, Faculty of Veterinary Medicine, Banda Aceh, Indonesia

• Prof. Jan Slapeta / University of Sydney, School of Veterinary Science, Sydney, Australia

• Prof. Domenico Otranto / University of Bari, Department of Veterinary Medicine, Bari, Italy

• Prof. Pilar Foronda Rodríguez / Universidad de La Laguna, Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Spain

• Dr. Nicholas Morant, OptiGene Limited, Horsham, UK

Contact

Prof. MVDr. David Modry, Ph.D. / Biology Center of Czech Academy of Sciences, České Budějovice, Czech Republic, 

email: modrydav@gmail.com 

Background

The Asian liver fluke Opisthorchis viverrini is intensively transmitted in Southeast Asia (SEA), particularly Lao PDR, Thailand and Cambodia. The helminth adult worm lives in human bile ducts of the liver where it causes a multitude of severe pathologies including cholangiocarcinoma (CCA), a fatal bile duct cancer. While in Northeast Thailand research on control tools and public health interventions have much advanced over the past decades, progress made in research and disease control is limited in Lao PDR and Cambodia and the interventions are rather temporary and focal.

There are major challenges for the successful control of O. viverrini infection and related morbidity. Firstly, the currently widely available diagnostic techniques (e.g. Kato-Katz) have a low sensitivity. Secondly, the extent of morbidity (disease) associated with the O. viverrini infection is unknown in many O. viverrini endemic settings. Thirdly, given the lack of adequate regional estimations of O. viverrini infection and the related mortality and morbidity, the currently employed level of control initiatives cannot be adequate planned.

The Project

Our project consortium, consisting of four institutions in Switzerland, Thailand, Lao PDR and Cambodia, each having several decades of experience in Asian liver fluke research and control, aims to develop new tools to control of O. viverrini infection and associated morbidity and mortality in SEA region. Our objectives are (i) to regionally validate a promising rapid diagnostic tests for O. viverrini infection in field sites in Cambodia, Lao PDR and Thailand; (ii) to compile existing data on O. viverrini infection and associated mortality and morbidity in Cambodia, Lao PDR and Thailand and complement them with additional survey data in areas where only sparse information is available; and (iii) to predict the risk of O. viverrini infection and related mortality and morbidity across Southeast Asia.

The Science

This transnational project will lead into a SEA regional view of O. viverrini infection and related morbidity and mortality. For objective (i), a field validation of the urine based detection of circulating O. viverrini will be performed. Two promising tests will be validated: A urine- and a corpro-antigen based diagnostic test, which have a documented high potential for further development. The validation will take into account the different levels of endemicity of O. viverrini infection, and the helminthic co-infections. It will be performed in settings in Lao PDR, Thailand and Cambodia. For objective (ii) an database will be created where existing geo-localized data on O. viverrini infection and associated morbidity will be combined with newly surveyed data. A systematic review of published literature on O. viverrini infection, and related morbidity and mortality will be conducted to achieve a most comprehensive database. For objective (iii), the database will be used for the prediction of O. viverrini infection, morbidity and mortality in area where no data is available and across all three endemic countries by using a well-established Bayesian geo-statistical modelling approach.

The Team

Prof Penelope Vounatsou and Prof Peter Odermatt, Swiss Tropical and Public Health Institute, Basel, Switzerland

Dr. Somphou Sayasone, Lao Tropical and Public Health Institute, Ministry of Health, Vientiane, Lao PDR

Dr. Virak Khieu, National Centre for Parasitology, Entomology and Malaria Control, Ministry of Health, Phnom Penh, Cambodia

Professor Paiboon Sithithaworn, Parasitology Department and Cholangiocarcinoma Research Institute, Khon Kaen University (KKU), Khon Kaen, Thailand

Contact

Professor Peter Odermatt, Swiss Tropical and Public Health Institute (Swiss TPH), Epidemiology and Public Health Department, Basel, Switzerland, Email: peter.odermatt@swisstph.ch

Featured image from unsplash.com

Background

Streptococcus pneumoniae, also known as the pneumococcus, is a Gram-positive pathogen recognized as a major cause of pneumonia worldwide. It resides as a commensal in the nasopharynx of healthy carriers, but in susceptible individuals this bacterium can spread to other body locations and cause life-threatening disease. The main group risks are the elderly, immunocompromised people and infants. In fact, approximately 900,000 children die each year due to pneumococcal disease, of which >90% occur in developing countries. In addition, a high number of pneumococcal infection cases are diagnosed in developed countries and can be associated with high morbidity in children and are an important factor that influences quality of life and produces significant mortality in adults. There are licensed polysaccharide-based vaccines to prevent pneumococcal infections, but their efficacy is limited. Therefore, pneumococcal community-acquired pneumonia (CAP) remains as an important health problem and once it has occurred, early diagnosis with accurate diagnostic methods is essential in order to provide patients with prompt and appropriate therapy. The ability to identify pneumococci as a causative agent in lung infections is quite limited and blood cultures are often negative. Serological diagnosis of pneumococcal disease based on a single antigen is often challenging, due to the interference of natural antibodies elicited by previous colonization events and the antigenic variability. Therefore, to better discriminate between diseased and healthy people, a combination of antigens would be desirable.

The Project

The aim of PNEUMOFLUIDICS is to develop an innovative point-of-care diagnostic for the early detection of Streptococcus pneumoniae (pneumococcus) infections on a serological basis. Results of multiplex analyses will be transferred to a microfluidic protein array (MPA), i.e. a biosensor on which proteins are immobilized and on which a novel serodiagnostic method can be established with minimal serum samples.

The Science

Research aims to develop a sensitive and quantitative tests for the rapid and specific detection of pneumococcal infections. For the validation of a microfluidic protein array (MPA), the detection of IgM antibodies as well as specific IgG antibodies will be performed in larger patient cohorts using initially well-established multiplex platforms for pneumococcal antigens. Selected pneumococcal antigens can also be used for immunostrips that will be probed with independent sets of patient sera. These immunostrips are a diagnostic test can be an easy-to-use tool for diagnosis in healthcare systems, especially in low-resource areas. The pneumococcal-specific MPA will be further used for a broad range of applications such as monitoring epidemiological episodes or discovering new protein vaccine candidates. This strategy will help to distinguish between patients with different diseases. The multiplex platforms or MPA can be employed in epidemiological surveillance programs to monitor possible outbreaks of pneumococcal disease around the world.

The Team

The PNEUMOFLUIDICS partners are:

• Coordinator : Prof. Dr. Sven Hammerschmidt,  Department of Molecular Genetics and Infection Biology, Interfaculty Institute of Genetics and Functional Genomics, Center for Functional Genomcis of Microbes,Universität Greifswald, Germany
• Brio Apps AlphaSip S.L. (BAA), Zaragoza, Spain
• Prof. Dr. Manuel J. Rodríguez Ortega, Departamento de Bioquímica y Biología Molecular, Edificio "Severo Ochoa", planta baja Campus de Rabanales, Universidad de Córdoba, Spain (subpartner of Brio Apps Alphasip)
• Prof Dr. Shinta Purwanto, Universitas Sam Ratulangi (USR), Jalan Kampus Bahu Malalayang,North Sulawesi Utara, Indonesia
• Dodi Safari, PhD, Eijkman Institute for Molecular Biology, Jl. Diponegoro no 69, Jakarta, Indonesia 10430 (associated partner)
• Dr. Moh Moh Htun, MBBS, Director (Research), Biomedical Research Centre (BRC), Department of Medical Research, Dagon Township, Yangon 11191, Myanmar

Contact: 

Prof. Dr. Sven Hammerschmidt

Featured image from:  Hammerschmidt, S., S. Wolff, A. Hocke, S. Rosseau, E. Muller, and M. Rohde. 2005.